ES2687706T3 - Anticuerpos útiles en la inmunización pasiva contra la gripe - Google Patents

Anticuerpos útiles en la inmunización pasiva contra la gripe Download PDF

Info

Publication number
ES2687706T3
ES2687706T3 ES11796555.8T ES11796555T ES2687706T3 ES 2687706 T3 ES2687706 T3 ES 2687706T3 ES 11796555 T ES11796555 T ES 11796555T ES 2687706 T3 ES2687706 T3 ES 2687706T3
Authority
ES
Spain
Prior art keywords
ser
thr
val
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11796555.8T
Other languages
English (en)
Spanish (es)
Inventor
Lawrence M. Kauvar
Stote Ellsworth
William Usinger
Krista Maureen Mccutcheon
Minha Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trellis Bioscience Inc
Original Assignee
Trellis Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trellis Bioscience Inc filed Critical Trellis Bioscience Inc
Application granted granted Critical
Publication of ES2687706T3 publication Critical patent/ES2687706T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES11796555.8T 2010-06-17 2011-06-17 Anticuerpos útiles en la inmunización pasiva contra la gripe Active ES2687706T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US35597810P 2010-06-17 2010-06-17
US355978P 2010-06-17
US201161443103P 2011-02-15 2011-02-15
US201161443103P 2011-02-15
US201161445455P 2011-02-22 2011-02-22
US201161445455P 2011-02-22
PCT/US2011/040982 WO2011160083A1 (en) 2010-06-17 2011-06-17 Antibodies useful in passive influenza immuization

Publications (1)

Publication Number Publication Date
ES2687706T3 true ES2687706T3 (es) 2018-10-26

Family

ID=45348575

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11796555.8T Active ES2687706T3 (es) 2010-06-17 2011-06-17 Anticuerpos útiles en la inmunización pasiva contra la gripe

Country Status (12)

Country Link
US (1) US10676520B2 (OSRAM)
EP (1) EP2582721B1 (OSRAM)
JP (1) JP6050747B2 (OSRAM)
KR (1) KR101849738B1 (OSRAM)
CN (2) CN103209994B (OSRAM)
AU (2) AU2011268072C1 (OSRAM)
BR (1) BR112012032185A2 (OSRAM)
CA (1) CA2839421C (OSRAM)
DK (1) DK2582721T3 (OSRAM)
ES (1) ES2687706T3 (OSRAM)
RU (1) RU2635999C2 (OSRAM)
WO (1) WO2011160083A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10654915B2 (en) 2011-12-05 2020-05-19 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
JP6386465B2 (ja) 2012-11-13 2018-09-05 ジェネンテック, インコーポレイテッド 抗ヘマグルチニン抗体及び使用方法
BR112015022623A2 (pt) 2013-03-14 2017-07-18 Contrafect Corp composição e métodos baseados em anticorpos neutralizantes, administrados por via intranasal para eficácia terapêutica melhorada
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
CN106795216B (zh) * 2014-02-04 2021-04-20 抗非特公司 可用于被动流感免疫的抗体及其组合物、组合和使用方法
EP3119802B1 (en) * 2014-03-20 2019-12-04 InflaRx GmbH Inhibitors of c5a for the treatment of viral pneumonia
TWI701258B (zh) 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
AU2017222564A1 (en) 2016-02-24 2018-09-06 Visterra, Inc. Formulations of antibody molecules to influenza virus
SG10201912842VA (en) 2016-07-14 2020-02-27 Bioarctic Ab Brain delivery protein
US20210052719A1 (en) * 2017-12-29 2021-02-25 Development Center For Biotechnology A universal vaccine against influenza
MX2020007772A (es) 2018-01-26 2020-09-18 Regeneron Pharma Anticuerpos humanos contra hemaglutinina de influenza.
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235708B1 (en) 1998-11-20 2001-05-22 Zymogenetics, Inc Testis-specific cystatin-like protein cystatin T
US20020006656A1 (en) 1999-12-23 2002-01-17 Holloway James L. Zcys5: a member of the cystatin superfamily
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
JP2006519775A (ja) 2003-03-07 2006-08-31 メルク エンド カムパニー インコーポレーテッド インフルエンザウイルスワクチン
AU2004260884B2 (en) * 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
RU2366662C2 (ru) * 2003-07-23 2009-09-10 Фуджирибайо Инк. Моноклональное антитело к вирусу типа а гриппа и устройство для иммунного анализа с использованием антитела
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
EP2522678A1 (en) 2006-05-15 2012-11-14 Sea Lane Biotechnologies, LLC Neutralizing antibodies to influenza viruses
HRP20130163T1 (hr) * 2006-09-07 2013-03-31 Crucell Holland B.V. Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2009079259A2 (en) * 2007-12-06 2009-06-25 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
CN102046656A (zh) * 2008-03-28 2011-05-04 航道生物技术有限责任公司 针对病毒抗原的中和性分子
RU2553325C2 (ru) * 2008-07-25 2015-06-10 Институт Фо Ресёч Ин Биомедицин Нейтрализующие антитела против вируса гриппа а и их использование
CL2009001735A1 (es) * 2008-08-19 2010-02-19 Regeneron Pharma Anticuerpo humano o fragmento de union a antigeno del mismo que une e inhibe actividad de ligando del activador del receptor de nf-kb (rankl); adn codificante; vector de expresion; metodo para producir dicho anticuerpo; composicion farmaceutica que lo comprende; uso para atenuar o inhibir enfermedad o condicion mediada por rankl
SG172333A1 (en) 2008-12-24 2011-07-28 Temasek Life Sciences Lab Ltd Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof
SI2552485T1 (sl) 2010-03-26 2017-05-31 Pomona Ricerca S.R.L. Imunoglobulini polne dolžine igg izotipa, sposobni prepoznave heteropodtipskega nevtralizacijskega epitopa na hemagglutininskem izvornem področju in njih uporaba kot zdravilo proti gripi
US8900590B2 (en) * 2010-08-12 2014-12-02 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
WO2012045001A2 (en) * 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor

Also Published As

Publication number Publication date
AU2017203924B2 (en) 2019-08-08
EP2582721A1 (en) 2013-04-24
DK2582721T3 (en) 2018-10-01
EP2582721B1 (en) 2018-08-22
CA2839421A1 (en) 2011-12-22
BR112012032185A2 (pt) 2016-10-11
KR20130137584A (ko) 2013-12-17
CA2839421C (en) 2019-12-03
AU2011268072B2 (en) 2017-03-09
CN103209994B (zh) 2016-10-12
US20120020971A1 (en) 2012-01-26
US10676520B2 (en) 2020-06-09
AU2011268072C1 (en) 2017-10-19
KR101849738B1 (ko) 2018-04-17
RU2013102073A (ru) 2014-07-27
CN106397584A (zh) 2017-02-15
AU2011268072A1 (en) 2013-01-31
JP6050747B2 (ja) 2016-12-21
AU2011268072A2 (en) 2013-02-28
WO2011160083A1 (en) 2011-12-22
EP2582721A4 (en) 2013-11-20
RU2635999C2 (ru) 2017-11-17
JP2013531993A (ja) 2013-08-15
AU2017203924A1 (en) 2017-07-06
CN103209994A (zh) 2013-07-17

Similar Documents

Publication Publication Date Title
ES2687706T3 (es) Anticuerpos útiles en la inmunización pasiva contra la gripe
AU2012347878B2 (en) Antibodies useful in passive influenza immunization
CN108640989B (zh) 可结合并中和b型流感病毒的人类结合分子及其用途
KR102602417B1 (ko) G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법
KR102701479B1 (ko) B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법
AU2022202819C1 (en) Antibody-mediated neutralization of Chikungunya virus
KR20210113936A (ko) 항-코로나바이러스 항체 및 사용 방법
KR20220158053A (ko) 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단클론 항체
KR20220038415A (ko) 엔테로바이러스 d68에 대한 인간 모노클로날 항체
CN107428819B (zh) 强力地中和狂犬病毒和其它狂犬病毒属病毒的抗体和其用途
KR101900435B1 (ko) 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체
KR20240006575A (ko) SARS-CoV-2에 대한 사람 중화 모노클로날 항체 및 이의 용도
KR20190077306A (ko) 항-o2 항체 및 이의 용도
AU2025201226A1 (en) Monoclonal antibodies and cocktails for treatment of Ebola infections
KR102880907B1 (ko) 한타바이러스에 대한 인간 모노클로날 항체 및 이의 사용 방법
CN114685653B (zh) 抗新冠病毒受体结合区域表位中和抗体及其应用
CN102238963A (zh) 完全人源性流感m2特异性抗体
KR102467943B1 (ko) 항-rsv 항체 및 이를 포함하는 약학적 조성물
CN111196848A (zh) 抗流感病毒的全人中和性抗体26Ab及其应用
AU2020273365A1 (en) Human antibodies to Ross River virus and methods of use therefor
CN116406375A (zh) 抗SARS-CoV-2刺突蛋白的三聚体抗体
CN117715930A (zh) 抗体
EA049454B1 (ru) ЧЕЛОВЕЧЕСКИЕ МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА К КОРОНАВИРУСУ ТЯЖЕЛОГО ОСТРОГО РЕСПИРАТОРНОГО СИНДРОМА 2 (SARS-CoV-2)
CN117836322A (zh) 针对SARS-CoV-2的人中和单克隆抗体及其用途
NZ729856B2 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof